Diethylpropion
Tenuate, Tepanil (diethylpropion) is a small molecule pharmaceutical. Diethylpropion was first approved as Tepanil on 1982-01-01. It is used to treat obesity in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Diethylpropion hydrochloride
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TEPANIL | 3M | N-011673 DISCN | 1982-01-01 | 1 products |
TEPANIL TEN-TAB | 3M | N-017956 DISCN | 1982-01-01 | 1 products |
TENUATE | Nostrum Laboratories | N-011722 DISCN | 1982-01-01 | 1 products, RLD |
TENUATE DOSPAN | Nostrum Laboratories | N-012546 DISCN | 1982-01-01 | 1 products, RLD |
TENUATE | Sanofi | N-017668 DISCN | 1982-01-01 | 1 products |
TENUATE | Sanofi | N-017669 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
diethylpropion hydrochloride | ANDA | 2023-06-19 |
tepanil | 2006-07-26 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
obesity | EFO_0001073 | D009765 | E66.9 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Loiasis | D008118 | B74.3 | — | 1 | — | 1 | — | 2 | |
Infections | D007239 | EFO_0000544 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Filarial elephantiasis | D004605 | EFO_0007272 | B74.0 | — | 3 | 2 | — | 3 | 8 |
Yaws | D015001 | EFO_0007548 | A66 | — | 1 | 1 | — | — | 2 |
Trachoma | D014141 | A71 | — | — | 1 | — | — | 1 | |
Scabies | D012532 | B86 | — | — | 1 | — | — | 1 | |
Strongyloidiasis | D013322 | EFO_0007501 | B78 | — | — | 1 | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Parasitic diseases | D010272 | EFO_0001067 | B88 | — | — | — | — | 1 | 1 |
Onchocerciasis | D009855 | EFO_0007402 | B73 | — | — | — | — | 1 | 1 |
Filariasis | D005368 | B74 | — | — | — | — | 1 | 1 | |
Mansonelliasis | D008368 | EFO_0007357 | B74.4 | — | — | — | — | 1 | 1 |
Helminthiasis | D006373 | EFO_1001342 | B65-B83 | — | — | — | — | 1 | 1 |
Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | DIETHYLPROPION |
INN | amfepramone |
Description | Diethylpropion is an aromatic ketone that is propiophenone in which one of the hydrogens alpha- to the carbonyl is substituted by a diethylamino group. A central stimulant and indirect-acting sympathomimetic, it is an appetite depressant and is used as the hydrochloride as an anoretic in the short term management of obesity. It has a role as an appetite depressant. It is a tertiary amine and an aromatic ketone. It is functionally related to a propiophenone. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCN(CC)C(C)C(=O)c1ccccc1 |
Identifiers
PDB | — |
CAS-ID | 90-84-6 |
RxCUI | — |
ChEMBL ID | CHEMBL1194666 |
ChEBI ID | 4530 |
PubChem CID | 7029 |
DrugBank | DB00937 |
UNII ID | Q94YYU22B8 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 644 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
100 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more